Published in final edited form as:

Spine J. 2015 May 1; 15(5): 1060–1069. doi:10.1016/j.spinee.2015.02.003.

Intact Glycosaminoglycans from intervertebral disc-derived notochordal cell conditioned media inhibits neurite growth while maintaining neuronal cell viability

Devina Purmessur¹, Marisa C Cornejo¹, Samuel K Cho¹, Peter J Roughley², Robert J Linhardt³, Andrew C Hecht¹, and James C Iatridis¹

¹ Leni & Peter W. May Department of Orthopedics, Icahn School of Medicine at Mount Sinai, New York, NY 10029

²Shriners Hospital for Children, Montreal, QC, Canada

³Biocatalysis & Metabolic Engineering, Rensselaer Polytechnic Institute, Troy, NY, 12180

Abstract

BACKGROUND CONTEXT—Painful human intervertebral discs (IVDs) exhibit nerve growth deep into the IVD. Current treatments for discogenic back pain do not address the underlying mechanisms propagating pain and are often highly invasive or only offer temporary symptom relief. The notochord produces factors during development that pattern the spine and inhibit growth of dorsal root ganglia (DRG) axons into the IVD. We hypothesize that notochordal cell (NC) conditioned medium (NCCM) includes soluble factors capable of inhibiting neurite growth and may represent a future therapeutic target.

PURPOSE—To test if NCCM can inhibit neurite growth and to determine if NC-derived Glycosaminoglycans (GAGs) are necessary candidates for this inhibition.

STUDY DESIGN—Human neuroblastoma (SH-SY5Y) cells and rat dorsal root ganglion (DRGs) cells were treated with NCCM in 2D culture in vitro and digestion and mechanistic studies determined if specific GAGs were responsible for inhibitory effects.

METHODS—NCCM was generated from porcine nucleus pulposus tissue that was cultured in DMEM for 4 days. A dose study was performed using SH-SY5Y cells that were seeded in basal medium for 24hrs and neurite outgrowth and cell viability were assessed following treatment with basal or NCCM (10% and 100%) media for 48hrs. GAGs from NCCM were characterized using multiple digestions and liquid chromatography mass spectroscopy (LC-MS). Neurite growth was assessed on both SH-SY5Y and DRG cells following treatment with NCCM with and without GAG digestion.

© 2015 Published by Elsevier Inc.

Corresponding author: Devina Purmessur on behalf of James C Iatridis Leni & Peter W. May Department of Orthopedics Icahn School of Medicine at Mount Sinai One Gustave L. Levy Place Box 1188 New York, NY 10029 devina.purmessur@mssm.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

RESULTS—NCCM significantly inhibited neurite outgrowth from SH-SY5Y cells compared to Basal controls without dose or cytotoxic effects; % neurite expressing cells were 39.0 ± 2.9 , 27.3 ± 3.6 & 30.2 ± 2.7 , and mean neurite length was $60.3 \pm 3.5 \mu\text{m}$, $50.8 \pm 2.4 \mu\text{m}$, $53.2 \pm 3.7 \mu\text{m}$ for Basal, 10% NCCM & 100% NCCM, respectively. Digestions and LC-MS determined that Chondroitin-6-Sulfate was the major GAG chain in NCCM. Neurite growth from SH-SY5Y and DRG cells was not inhibited when cells were treated with NCCM with digested chondroitin sulfate (CS).

CONCLUSIONS—Soluble factors derived from NCCM were capable of inhibiting neurite outgrowth in multiple neural cell types without any negative effects on cell viability. Cleavage of GAGs via digestion was necessary to reverse the neurite inhibition capacity of NCCM. We conclude that intact GAGs such as CS secreted from NCs are potential candidates that could be useful to reduce neurite growth in painful IVDs.

Keywords

Notochordal cells; Intervertebral disc; Neuronal cells; Glycosaminoglycans; Chondroitin sulfate; Neurite outgrowth

Introduction

Low back pain is the leading global cause of disability causing substantial socioeconomic burden and intervertebral disc (IVD) disease is commonly implicated in its pathogenesis [1, 2]. While the etiology of discogenic back pain is not completely understood, back pain patients have demonstrated increased nerve growth into diseased IVDs [3]. Analgesics provide only short-term pain relief and current biological strategies to treat painful IVDs focus largely on repair and regeneration of the IVD rather than targeting the source of pain itself. There is a need to develop therapies that focus on the mechanisms associated with the induction and propagation of discogenic back pain, and addressing neurovascular invasion is a natural target [4].

The healthy immature IVD is largely avascular and aneural, and rich in proteoglycans. The gelatinous nucleus pulposus (NP) is surrounded circumferentially by the fibrous annulus fibrosus (AF) and contained cranially and caudally by the cartilage endplates providing the IVD with the ability to withstand high mechanical forces and maintain motion [5]. Aging and degeneration of the IVD results in increased matrix degradation, pro-inflammatory cytokine expression, decreased water content, and inferior mechanical properties [6]. These degenerative changes, including fissures, may provide a permissive micro-environment for neurovascular growth and sensitization of nerve fibers in the IVD [7]. Small unmyelinated nociceptive neurons expressing the neuropeptide Substance P and axonal elongation marker GAP43 have been demonstrated to grow into the painful human IVD [3, 8]. These nerves also express the high affinity receptor for nerve growth factor (NGF), tyrosine kinase A (TrkA) and accompany microvascular blood vessels that express NGF [9]. The likely sources of neoinnervation and neovascularization are defects in the AF or vertebral endplates [9]. Neurovascularization has been identified in posterior radial and transdiscal tears of human cadaveric IVDs [10] and in such tears a decrease in the stress profile along the defect and also focal depletion of proteoglycans was observed, providing a path for

nerves and blood vessels to grow into the IVD [7]. Defects in the vertebral endplate are also associated with neoinnervation where nerve growth has shown to be greatest in fibrovascular end-plate marrow defects compared to annular tears or other endplate pathologies [11].

The healthy IVD produces factors with the ability to inhibit growth of nerves and blood vessels into the IVD, yet expression of such factors decreases with age and their absence may be associated with promoting neurovascular growth in diseased states [7, 12-14]. Disc cells express vascular endothelial growth factor (VEGF), NGF and brain derived neurotrophic factor (BDNF), and expression of these nerve promoting factors increases with the severity of degeneration [15-18]. These growth factors are also up-regulated by the pro-inflammatory cytokines TNF α and IL-1 β in vitro, and as such they may enhance the increase in expression observed with disease progression. The disc also produces neuropeptides (i.e. Substance P) involved in pain perception which can up-regulate pro-inflammatory cytokines themselves and increase with severity of degeneration [19, 20]. Human neuronal cells co-cultured with human degenerate NP cells show increased neurite growth [21], while co-culture with human NP cells isolated from the healthy non-degenerate IVDs had inhibitory effects on neurite growth. Human aggrecan from the healthy IVD can inhibit both neurite growth and endothelial migration in vitro and taken together these studies suggest that soluble factors from the healthy IVD could be harnessed to repel neurovascular growth in the painful IVD [12, 13].

Recapitulation of the processes that occur during developmental patterning of the healthy immature notochordal cell-rich IVD may help inform therapeutic strategies to treat painful IVD degeneration [4]. The notochord patterns the IVD during development through secretion of diverse developmental ligands that give rise to the aneural and avascular structure. These include soluble neurovascular repulsive factors such as semaphorin3A and noggin [22, 23]. Chondroitin sulfated proteoglycans expressed by the notochordal sheath are also associated with neuronal patterning and inhibition during development of the spine [24]. Understanding the processes that occur during development may inform treatments for discogenic back pain, and we believe that such natural processes should be emulated to enhance therapeutic strategies. A number of species such as pig and rabbit retain notochordal cells (NCs) from development through to adulthood and do not experience the disc disease common in humans [25, 26]. As a consequence NCs have received much attention with regard to the possible mechanisms associated with their loss and also their therapeutic potential [4, 27-30]. It has previously been shown that notochordal cell conditioned media (NCCM) promotes a healthy NP phenotype in human degenerate NP cells, human mesenchymal stem cells and mouse induced pluripotent stem cells [31-35] via stimulation of substantial glycosaminoglycan (GAG) production and up-regulation of phenotypic markers. The long term objectives of this work are to utilize factors secreted by NCs to treat painful IVDs by preventing or limiting neurovascularization in the diseased state. We previously demonstrated that notochordal-rich NP tissue contains soluble factors that have the capacity to inhibit axonal growth, namely semaphorin3A and chondroitin sulfate and showed increased proteoglycan accumulation following mechanical stimulation of NCs [29]. However, it is not known if NCCM is capable of inhibiting axonal growth and what soluble factors in NCCM are responsible for such neurite inhibition.

The aim of this study was to examine the dose effects of NCCM on neurite growth and to establish the soluble factors necessary for these observed effects. We investigated human neuroblastoma (SH-SY5Y) cells because they are a well characterized readily available human neural cell source previously used for these types of studies [12, 21]. For mechanistic studies we validate the effects also on rat DRG cells due to their physiological relevance since DRGs are responsible for innervating the IVD in situ and human DRGs are not readily available. NCCM was derived from porcine NP tissue which is comprised of ~80% NCs [33]. GAGs in NCCM were characterized using a series of enzymatic digestions and NCCM digested with chondroitinase ABC was then used to treat neural cells to probe the mechanism of GAGs as a potential neural inhibitory factor in NCCM.

Materials and Methods

SH-SY5Y and DRG cell culturing

All materials and reagents were obtained from Sigma-Aldrich unless otherwise stated. Human neuroblastoma SH-SY5Y cells (Passage 19) (Sigma-Aldrich, # 94030304) were maintained in Eagle's Minimum Essential Medium (EMEM) (ATCC, # 30-2003) and F-12K medium (ATCC, # 30-2004) in 1:1 ratio with 10% fetal bovine serum and 1% Penicillin/Streptomycin at 37°C 5% CO₂ and expanded to 70% confluence prior to treatment. Primary rat DRGs (Innoprot) were maintained at 37°C 5% CO₂ and cultured according to the manufacturer's instructions. DRG cells were cultured in Neuronal Medium (Cat # #1521) supplemented with Neural Growth Serum and 1% Penicillin/Streptomycin) to produce Neuronal Supplemented Media.

Generation of notochordal cell conditioned media (NCCM)

Porcine spines (6 to 8 weeks of age) were obtained within 24 hours of death (Animal Facility Research 87 Inc., Boylston, MA, USA; animals are routinely slaughtered for human consumption (permit from USDA) and waste tissue taken for research) and notochordal-rich NP tissue aseptically dissected from a total of 6 spines (n=6) (Figure 1). NP tissue from 4 discs from the same spine were cultured in 50 mL falcon tubes with 30 mL of Basal media, which consisted of high glucose DMEM, 1x insulin transferrin & selenium (ITS), salt solution (5 M NaCl/0.4 M KCl) and 50 µg/mL ascorbic acid, and incubated (1% O₂, 5% CO₂ and 37°C) for 4 days to generate NCCM. Medium was then filtered through 3000 MW Amicon Ultra-15 (Millipore Bedford, MA USA) in order to remove small metabolites and waste products associated with altered pH, and the concentrate re-suspended in an equal volume of either fresh control SH-SY5Y Basal media (EMEM: F12K without FBS) or rat DRG Basal media (Neuronal Medium + growth serum).

Dose response study of NCCM on SH-SY5Y cells

SH-SY5Y cells were treated with NCCM at 100% and 10% or control Basal media. Cells were seeded at a density of 50,000 cells/well of a 6 well poly-D-lysine coated plate in 2 mL of EMEM: F12K with 10% FBS and 1% Penicillin/Streptomycin for 24 hours 37°C 5% CO₂. After incubation, wells were washed twice with 2 mL phosphate buffered saline (PBS) and then 2 mL of NCCM (n=6) at 100% concentration, NCCM at 10% in Basal media, or a Basal media control (SH-SY5Y Basal media: EMEM: F12K without FBS) were added. All

media conditions contained 40 ng/mL platelet derived growth factor (PDGF) to induce neurite growth. SH-SY5Y cells were incubated at 37°C 5% CO₂ for a further 48 hours.

Digestion of NCCM to investigate the content of GAGs in NCCM

A series of digestions were performed to investigate which GAGs are present in NCCM. NCCM (n=4) was pre-digested with either chondroitinase B (Chon-B) (Sigma # C8058), chondroitinase ABC (Chon-ABC) (Sigma # C3667), keratanase (Seikagaku AM INC, Japan # 100810-1) or heparinase II (Sigma # H6512) to digest dermatan sulfate (DS), chondroitin sulfate (CS) and DS, keratan sulfate (KS) or heparan sulfate (HS), respectively. GAG content of control and digested NCCM was assessed by the dimethyl methylene blue (DMB) assay [36]. The DMB assay measured the amount of intact GAG in NCCM treated with the enzymes. DMB analyses were performed on both NCCM samples and NCCM with selected enzymatic digestions. CS (Sigma # C4384), DS (Sigma # C3788), HS (Sigma # H7640) and KS (provided by XXXXXXXX) standard curves were used as appropriate. Digested NCCM was then normalized to the undigested control to give % degradation for each enzyme treatment.

To investigate the CS composition of NCCM, GAGs were isolated, purified and fractionated as described previously [37, 38]. Liquid chromatography mass spectroscopy (LC-MS) analyses were performed on an Agilent 1200 LC/MCD instrument (Agilent Technologies, Inc., Wilmington, DE) and quantitation analysis of disaccharides performed using calibration curves by separation of increasing amounts of unsaturated disaccharide standards. Linearity was assessed based on amount of disaccharide and peak intensity in extract ion chromatography.

Treatment of SH-SY5Y cells and DRGs with NCCM pre-digested with chondroitinase ABC

Chon-ABC was the only enzyme to significantly digest GAGs in NCCM (see Results); therefore, we examined the effects of NCCM digested with Chon-ABC on SH-SY5Y and DRG cells. NCCM (100%) (n=4) was pre-digested with Chon-ABC at 0.05U/mL at 37°C for 30 minutes to generate the NCCM + Chon ABC media group. SH-SY5Y cells were then seeded as described above for NCCM dose study treatment with the addition of the NCCM + Chon ABC group. SH-SY5Y cells were incubated at 37°C 5% CO₂ for 48 hours. For rat DRG cells, cells were seeded onto laminin-coated Poly-D-Lysine 24-well plates at a cell density of 8,333 cells per well in 1 mL of DRG Basal media, and DRG cells were incubated at 37°C 5% CO₂ for 4 hours to allow adherence. After incubation DRG cells were treated with 1 mL of DRG Basal media, 100% NCCM (n=4) in DRG Basal media and 100% NCCM pre-digested with Chon-ABC together with recombinant rat beta-NGF at 100 ng/ml and incubated for 48 hours, as for SH-SY5Y.

Cell viability

Cell viability of SH-SY5Y and rat DRG cells was assessed using the Live/Dead assay (L3224, Invitrogen). Briefly, cells were incubated for 15 minutes in 10 mL of high glucose DMEM containing 10 µL of 2 mM Ethidium Homodimer-1 (ETH) stock and 20 µL of 4 mM Calcein AM stock in at 37°C protected from light. Following incubation, cell viability was

assessed and images captured at 10X magnification using a fluorescent inverted Zeiss microscope (Emission/ excitation; Calcein = 494/517 nm and ETH = 528/617 nm).

Image analysis

To assess neurite growth from SH-SY5Y and DRG cells following 48 hours incubation, 10 phase contrast images at 10x magnification were captured using a Zeiss inverted microscope and Axiovision software for each treatment group and the percentage of neurite expressing cells, mean neurite length and total numbers of neurites were calculated using ImageJ software for both SH-SY5Y and DRG cells [12, 21]. For the analysis, a neurite was defined as a cell process greater than 20µm, for branching neurites only the longest branch was traced and only cells with the entire cell body and neurite in the field of view were included (Figure 2).

Statistics

For all neurite growth and DMB assay data, a one way ANOVA with post hoc Tukey test was performed comparing Basal to NCCM 10% and NCCM 100% for SH-SY5Y cells. For GAG characterization/digestion studies, the undigested NCCM group (Control) was compared to different enzyme concentration groups for each respective enzyme assessed (Chon-ABC, Chon-B, keratanase and heparanase). For mechanistic studies, comparisons were made between Basal, NCCM and NCCM+Chon-ABC groups for SH-SY5Y and DRG cells. GraphPad Prism 3 (La Jolla, Ca) was used with $p < 0.05$ significant.

Results

Effects of NCCM dose on SH-SY5Y cells

NCCM at doses of 10 and 100% did not demonstrate any detrimental effects on cell viability for SH-SY5Y cells with no significant differences compared to Basal controls (Green calcein stained cells = live; red ethidium stained cells = dead) (Figures 3A-B). Notable differences in cell morphology were observed for SH-SY5Y cells treated with NCCM at both 10 and 100% (Figures 4A-C) with NCCM-treated cells exhibiting a more spread out less elongated appearance with fewer neurites than the Basal condition. NCCM significantly reduced the % of neurite expressing cells and mean neurite length at both 10 and 100% compared to the Basal control group with no differences between doses (Figures 4D-F) ($P < 0.05$). No significant effects were observed on the total number of neurites.

Digestion of NCCM to investigate the abundance of intact GAGs in NCCM

Chon-ABC was the only enzyme to significantly decrease the amount of GAG in NCCM at all doses assessed compared to untreated controls suggesting that CS/DS formed the predominant GAGs in NCCM (Figure 5A) ($P < 0.05$). To determine whether CS or DS forms the predominant GAG, NCCM was digested with Chon-B which specifically digests DS. At all doses assessed we observed no significant changes in GAG content compared to undigested NCCM, suggesting that CS forms the majority of GAG in NCCM. To ensure that Chon-B was active, as the suggested incubation conditions differed from that of Chon-ABC, we ran a DS positive control. DS was digested with the same concentrations of Chon-B as for Chon-ABC and decreases in GAG were observed at all doses, in particular for 0.1U/ml.

Keratanase and Heparanase at all doses did not degrade GAG in NCCM compared to NCCM controls, further confirming that CS was the dominant GAG in NCCM.

To determine the CS disaccharide composition of NCCM, GAGs were isolated, purified, and subject to digestion with Chondroitinase ACII and ABC followed by analysis using LC-MS with appropriate standards for identification and quantification. C-4-S, C-6-S and C-0-S disaccharides were identified in NCCM with a significantly greater % of C-6-S compared to either C-4-S or C-0-S alone (Figure 5B) ($P<0.05$) indicating that C-6-S is the most abundant disaccharide in NCCM.

Treatment of SH-SY5Y and DRG cells with NCCM pre-digested with chondroitinase ABC

SH-SY5Y cells treated with NCCM + Chon-ABC resembled that of Basal controls with an elongated appearance and significantly more neurites (Figures 6A-C) ($P<0.05$). NCCM + Chon-ABC was able to restore the % of neurite expressing cells back to Basal levels and significantly increased mean neurite length and total number of neurites compared to NCCM treatment alone (Figures 6D-F) ($P<0.05$). To investigate whether NCCM and Chon-ABC digested NCCM had similar effects on more physiologically relevant neuronal cell type, rat DRG cells were treated as described for SH-SY5Y cells. No qualitative changes in cell morphology were observed with any of the treatments, although NCCM significantly decreased % neurite expressing cells, mean neurite length, and total number of neurites (Figures 7A-F) ($P<0.05$). NCCM did not demonstrate any cytotoxic effects on DRG cell viability compared to Basal conditions (supplemental data). No differences were observed between Basal and NCCM + Chon-ABC groups for all parameters assessed, indicating that digestion of GAGs of which CS is the predominant form in NCCM restored rat DRG cells to Basal conditions.

Discussion

This study evaluated the hypotheses that soluble factors secreted from NCs can be used to inhibit neurite growth and that intact GAGs such as CS are likely important factors in this inhibitory process. NCCM generated from immature porcine NP tissue that is rich in NCs inhibited neurite growth in both human SH-SY5Y neuroblastoma and rat DRG cells. GAG from NCCM was characterized using digestion studies that targeted CS, DS, KS and HS and also used LC-MS to determine CS disaccharide composition. CS consisting largely of C-6-S disaccharides was determined to be the predominant GAG in NCCM and we suggest that CS in its intact form was a candidate factor for inducing the observed neurite inhibition. There was no dose effect of NCCM on this neural inhibiting characteristic and no loss of cell viability at high or low concentrations compared to controls. SH-SY5Y cells treated with NCCM demonstrated an altered cell morphology which may be associated with a change in cell phenotype. Results therefore suggest that intact GAGs produced from NCs could be utilized for therapeutic effect targeting neo-innervation into painful IVDs, and the lack of any observed cytotoxicity further suggests that components of NCCM are likely to be safe for surrounding neuronal structures.

Previous studies demonstrated that NP cells from the healthy human IVD have the ability to inhibit neurite growth from SH-SY5Y cells when in co-culture suggesting that these healthy

NP cells are able to produce soluble factors that have the potential to limit neoinnervation [21]. Rat NP and NC cells co-cultured in different ratios showed significant inhibition of neurite growth from rat DRGs [39], further corroborating these results. The results from our current study support the literature, demonstrating that soluble factors from healthy NP cells or immature NCs can inhibit neurite growth and suggests that intact GAGs such as CS are important neural inhibitory factors that can be produced by NCs and healthy NP cells. During early patterning of the spine, the notochordal sheath expresses CS. This is one of the mechanisms by which the notochord repels axonal elongation from DRGs along the midline [24]. Johnson et al. demonstrated that aggrecan derived from the mature human IVD can inhibit neurite growth, however when Chon-ABC was used to digest the CS side chains on the aggrecan core protein, its inhibitory effects were reduced [12]. Studies have suggested that a loss of proteoglycan during disc disease, together with a decrease in pressurization, may provide a permissive environment for nerve growth [7]. Therefore changes in CS/ proteoglycan content may be a key mechanism associated with neurovascular growth and pain during disease. Neo-angiogenesis has been suggested to be a precursor for neoinnervation in the painful degenerate IVD [9], providing the nerve fibers with an oxygen supply as the IVD is hypoxic and neurons will undergo apoptosis/cell death in these conditions[40]. As such NCCM was generated under hypoxic conditions to maintain NC cell phenotype and generation of soluble factors however neuronal cells were treated with NCCM in normoxic conditions to maintain neuronal cell viability.

During growth, aging and disease the IVD undergoes dramatic changes in matrix composition [41]. Specifically, the composition and length of GAG chains changes with aging as does the length of the aggrecan core protein [41]. There is a decrease in the length and number of CS side-chains in favor of KS and KS has been shown to have a reduced effect on neural inhibition compared to CS [12]. Early research demonstrated that the composition of CS subtypes in the IVD was primarily C-4-S and C-6-S [42]. C-6-S was abundant in the developing notochordal rich-NP and declined with aging, while the converse was true for C-4-S. However, more recent studies have suggested a role for native 7-D-4 CS sulfation motifs which contain a mix of C-4-S and C-6-S oligosaccharides in the IVD anlagen and they have been described as a “marker of tissue development” which decline with aging [43]. In our study we demonstrated that the major CS disaccharide in NCCM is C-6-S, suggesting that this disaccharide could likely be responsible for the observed inhibitory effects. Additional experiments such as rescue studies validating the role of C-6-S would be valuable but currently C-6-S is not commercially available. Both C-6-S and C-4-S disaccharides have been shown to inhibit neurite growth from embryonic neurons in cell culture however, their role with respect to adult neurons, such as those that innervate the adult IVD, are less clear [44, 45]. These studies suggest that free intact GAGs such as CS side-chains could be effective at inhibiting neurite growth and this is supported by work demonstrating that recombinant aggrecan depleted of chondroitin sulfated side-chains was unable to inhibit neurite extension [46]. At present, it is uncertain whether a specific CS sulfation pattern is required or any CS structure will suffice, or if other GAGs of low abundance are also important in repelling neurite extension. Answers to these key questions will be important for determining how to use intact CS in a therapeutic manner.

This study used multiple cell sources from different species; porcine-derived NCCM was used as the pig is rich in NCs and readily available in contrast to the human. The SH-SY5Y neuroblastoma cell line represents the most relevant human neural cell available. DRG cells were the most anatomically relevant cell population innervating the IVD, and were readily available to be isolated from rats unlike for humans. While this can complicate data interpretation, it does not detract from the ultimate conclusions. Autologous human derived NCCM is not a feasible treatment option in humans which lose their large vacuolated NCs during adolescence. Therefore, minimally invasive strategies using these NC-derived concepts rely on isolation and injection of specifically identified factors in NCCM. Our study points toward CS as a candidate factor for our observed neuronal inhibiting effects. Additional ligands present in NCCM, such as semaphorin3A and noggin, are also suggested as a mechanism for neuronal inhibition and avascular patterning of the IVD during development [22-24]. The presence of multiple anabolic and neural-inhibiting factors present in NCCM may have contributed to the lack of NCCM dose effects, giving more justification for the use of a single factor that may have the potential to repel invading nerves into the painful IVD. The lack of dose effects may also suggest that neural inhibition was saturated at 10%. Furthermore, it is possible that other factors can play a neural inhibiting role at lower GAG concentrations. It is also reasonable to stimulate the resident NP cells to produce a continuous source of CS rather than inject CS directly as a single dose. In general, we believe that maintaining, or restoring, the structure of the IVD as a barrier high in GAGs such as CS is a key element to repelling neural growth and pain.

In conclusion, our study demonstrated that intact GAGs are the principal neural inhibitory factors in NCCM; we hypothesize that restoration of the CS matrix barrier rich in C-6-S is essential to preventing neural growth and discogenic pain but note that additional low abundant GAGs that are difficult to detect may also play roles in neurite inhibition. We also demonstrated that human SH-SY5Y and rat DRGs have similar neurite growth behaviors in vitro suggesting both are reasonable cell choices for such screening studies but recommend the use of DRGs as a neuronal cell model of choice due to their greater physiological relevance. Soluble factors from NCs were not cytotoxic, suggesting these factors have the potential to be injected into the IVD with minimal detrimental effects on surrounding neuronal structures. Whether NCs produce an immature type of CS that is more inhibitory compared to mature NP cells remains unknown and represents a future area of exploration.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors gratefully acknowledge the technical assistance of Dr Svenja Illien-Junger and Ms Ilana Stock for NP tissue isolation and cell culture and Dr Lingyun Li for technical assistance with the disaccharide compositional analysis. The authors also acknowledge the support of Dr Hongyan Zhou with DRG cell culture. This study was supported by the NIH (R01 AR064157), Orthopaedic Education Research Foundation & S-13-50P of the AO Foundation

References

1. Katz JN. Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. *J Bone Joint Surg Am.* 2006; 88(Suppl 2):21–4. [PubMed: 16595438]
2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012; 380(9859):2163–96. [PubMed: 23245607]
3. Freemont AJ, Peacock TE, Goupille P, Hoyland JA, O'Brien J, Jayson MI. Nerve ingrowth into diseased intervertebral disc in chronic back pain. *Lancet.* 1997; 350(9072):178–81. [PubMed: 9250186]
4. Purmessur D, Cornejo M, Cho S, Hecht A, Iatridis J. Notochordal Cell–Derived Therapeutic Strategies for Discogenic Back Pain. *Global Spine Journal.* 2013
5. Humzah MD, Soames RW. Human intervertebral disc: structure and function. *The Anatomical record.* 1988; 220(4):337–56. [PubMed: 3289416]
6. Adams MA, Roughley PJ. What is intervertebral disc degeneration, and what causes it? *Spine.* 2006; 31(18):2151–61. [PubMed: 16915105]
7. Stefanakis M, Al-Abbasi M, Harding I, et al. Annulus fissures are mechanically and chemically conducive to the ingrowth of nerves and blood vessels. *Spine.* 2012; 37(22):1883–91. [PubMed: 22706090]
8. Coppes MH, Marani E, Thomeer RT, Groen GJ. Innervation of “painful” lumbar discs. *Spine.* 1997; 22(20):2342–9. discussion 9-50. [PubMed: 9355214]
9. Freemont AJ, Watkins A, Le Maitre C, et al. Nerve growth factor expression and innervation of the painful intervertebral disc. *J Pathol.* 2002; 197(3):286–92. [PubMed: 12115873]
10. Vernon-Roberts B, Moore RJ, Fraser RD. The natural history of age-related disc degeneration: the pathology and sequelae of tears. *Spine.* 2007; 32(25):2797–804. [PubMed: 18246000]
11. Fields AJ, Liebenberg EC, Lotz JC. Innervation of pathologies in the lumbar vertebral end plate and intervertebral disc. *The spine journal : official journal of the North American Spine Society.* 2013
12. Johnson WE, Caterson B, Eisenstein SM, Hynds DL, Snow DM, Roberts S. Human intervertebral disc aggrecan inhibits nerve growth in vitro. *Arthritis Rheum.* 2002; 46(10):2658–64. [PubMed: 12384924]
13. Johnson WE, Caterson B, Eisenstein SM, Roberts S. Human intervertebral disc aggrecan inhibits endothelial cell adhesion and cell migration in vitro. *Spine.* 2005; 30(10):1139–47. [PubMed: 15897827]
14. Tolofari SK, Richardson SM, Freemont AJ, Hoyland JA. Expression of semaphorin 3A and its receptors in the human intervertebral disc: potential role in regulating neural ingrowth in the degenerate intervertebral disc. *Arthritis research & therapy.* 2010; 12(1):R1. [PubMed: 20051117]
15. Abe Y, Akeda K, An HS, et al. Proinflammatory cytokines stimulate the expression of nerve growth factor by human intervertebral disc cells. *Spine.* 2007; 32(6):635–42. [PubMed: 17413467]
16. Lee JM, Song JY, Baek M, et al. Interleukin-1 β induces angiogenesis and innervation in human intervertebral disc degeneration. *J Orthop Res.* 2011; 29(2):265–9. [PubMed: 20690185]
17. Purmessur D, Freemont AJ, Hoyland JA. Expression and regulation of neurotrophins in the nondegenerate and degenerate human intervertebral disc. *Arthritis research & therapy.* 2008; 10(4):R99. [PubMed: 18727839]
18. Krock E, Rosenzweig DH, Chabot-Dore AJ, et al. Painful, degenerating intervertebral discs up-regulate neurite sprouting and CGRP through nociceptive factors. *Journal of cellular and molecular medicine.* 2014
19. Kepler CK, Markova DZ, Hilibrand AS, et al. Substance p stimulates production of inflammatory cytokines in human disc cells. *Spine.* 2013; 38(21):E1291–9. [PubMed: 23873242]
20. Richardson SM, Doyle P, Minogue BM, Gnanalingham K, Hoyland JA. Increased expression of matrix metalloproteinase-10, nerve growth factor and substance P in the painful degenerate intervertebral disc. *Arthritis research & therapy.* 2009; 11(4):R126. [PubMed: 19695094]

21. Richardson SM, Purmessur D, Baird P, Probyn B, Freemont AJ, Hoyland JA. Degenerate human nucleus pulposus cells promote neurite outgrowth in neural cells. *PloS one*. 2012; 7(10):e47735. [PubMed: 23091643]
22. Anderson CN, Ohta K, Quick MM, Fleming A, Keynes R, Tannahill D. Molecular analysis of axon repulsion by the notochord. *Development*. 2003; 130(6):1123–33. [PubMed: 12571104]
23. Reese DE, Hall CE, Mikawa T. Negative regulation of midline vascular development by the notochord. *Developmental cell*. 2004; 6(5):699–708. [PubMed: 15130494]
24. Masuda T, Fukamauchi F, Takeda Y, et al. Developmental regulation of notochord-derived repulsion for dorsal root ganglion axons. *Mol Cell Neurosci*. 2004; 25(2):217–27. [PubMed: 15019939]
25. Hunter CJ, Matyas JR, Duncan NA. Cytomorphology of notochordal and chondrocytic cells from the nucleus pulposus: a species comparison. *Journal of anatomy*. 2004; 205(5):357–62. [PubMed: 15575884]
26. Oegema TR Jr. The role of disc cell heterogeneity in determining disc biochemistry: a speculation. *Biochemical Society transactions*. 2002; 30(Pt 6):839–44. [PubMed: 12440929]
27. Guehring T, Nerlich A, Kroeber M, Richter W, Omlor GW. Sensitivity of notochordal disc cells to mechanical loading: an experimental animal study. *European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society*. 2010; 19(1):113–21.
28. Guehring T, Wilde G, Sumner M, et al. Notochordal intervertebral disc cells: sensitivity to nutrient deprivation. *Arthritis and rheumatism*. 2009; 60(4):1026–34. [PubMed: 19333932]
29. Purmessur D, Guterl CC, Cho SK, et al. Dynamic pressurization induces transition of notochordal cells to a mature phenotype while retaining production of important patterning ligands from development. *Arthritis research & therapy*. 2013; 15:R122. [PubMed: 24427812]
30. Gantenbein-Ritter B, Chan SC. The evolutionary importance of cell ratio between notochordal and nucleus pulposus cells: an experimental 3-D co-culture study. *European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society*. 2012; 21(Suppl 6):S819–25.
31. Abbott RD, Purmessur D, Monsey RD, Iatridis JC. Regenerative potential of TGFbeta3 + Dex and notochordal cell conditioned media on degenerated human intervertebral disc cells. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. 2012; 30(3):482–8. [PubMed: 21866573]
32. Korecki CL, Taboas JM, Tuan RS, Iatridis JC. Notochordal cell conditioned medium stimulates mesenchymal stem cell differentiation toward a young nucleus pulposus phenotype. *Stem cell research & therapy*. 2010; 1(2):18. [PubMed: 20565707]
33. Purmessur D, Schek RM, Abbott RD, Ballif BA, Godburn KE, Iatridis JC. Notochordal conditioned media from tissue increases proteoglycan accumulation and promotes a healthy nucleus pulposus phenotype in human mesenchymal stem cells. *Arthritis research & therapy*. 2011; 13(3):R81. [PubMed: 21627827]
34. Chen J, Lee EJ, Jing L, Christoforou N, Leong KW, Setton LA. Differentiation of mouse induced pluripotent stem cells (iPSCs) into nucleus pulposus-like cells in vitro. *PloS one*. 2013; 8(9):e75548. [PubMed: 24086564]
35. Potier E, Ito K. Using notochordal cells of developmental origin to stimulate nucleus pulposus cells and bone marrow stromal cells for intervertebral disc regeneration. *European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society*. 2013
36. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. *Biochimica et biophysica acta*. 1986; 883(2):173–7. [PubMed: 3091074]
37. Li B, Liu H, Zhang Z, Stansfield HE, Dordick JS, Linhardt RJ. Analysis of glycosaminoglycans in stem cell glycomics. *Methods Mol Biol*. 2011; 690:285–300. [PubMed: 21043000]
38. Yang B, Chang Y, Weyers AM, Sterner E, Linhardt RJ. Disaccharide analysis of glycosaminoglycan mixtures by ultra-high-performance liquid chromatography-mass spectrometry. *Journal of chromatography A*. 2012; 1225:91–8. [PubMed: 22236563]

39. Larsson K, Runesson E, Junevik K, Rydevik B, Brisby H. Effects of intervertebral disc cells on neurite outgrowth from dorsal root ganglion explants in culture. *Spine*. 2011; 36(8):600–6. [PubMed: 21124261]
40. Won SJ, Kim DY, Gwag BJ. Cellular and molecular pathways of ischemic neuronal death. *Journal of biochemistry and molecular biology*. 2002; 35(1):67–86. [PubMed: 16248972]
41. Roughley PJ. Biology of intervertebral disc aging and degeneration: involvement of the extracellular matrix. *Spine*. 2004; 29(23):2691–9. [PubMed: 15564918]
42. Hayes AJ, Benjamin M, Ralphs JR. Extracellular matrix in development of the intervertebral disc. *Matrix biology : journal of the International Society for Matrix Biology*. 2001; 20(2):107–21. [PubMed: 11334712]
43. Shu C, Hughes C, Smith SM, et al. The ovine newborn and human foetal intervertebral disc contain perlecan and aggrecan variably substituted with native 7D4 CS sulphation motif: spatiotemporal immunolocalisation and co-distribution with Notch-1 in the human foetal disc. *Glycoconjugate journal*. 2013; 30(7):717–25. [PubMed: 23756834]
44. Butterfield KC, Conovaloff A, Caplan M, Panitch A. Chondroitin sulfate-binding peptides block chondroitin 6-sulfate inhibition of cortical neurite growth. *Neuroscience letters*. 2010; 478(2):82–7. [PubMed: 20450957]
45. Zhang X, Bhattacharyya S, Kusumo H, Goodlett CR, Tobacman JK, Guizzetti M. Arylsulfatase B modulates neurite outgrowth via astrocyte chondroitin-4-sulfate: dysregulation by ethanol. *Glia*. 2014; 62(2):259–71. [PubMed: 24311516]
46. Beller JA, Kulengowski B, Kobraei EM, et al. Comparison of sensory neuron growth cone and filopodial responses to structurally diverse aggrecan variants, in vitro. *Experimental neurology*. 2013; 247:143–57. [PubMed: 23458191]

Figure 1. Study Design: Generation of Notochordal cell conditioned media (NCCM) and treatment of SH-SY5Y and DRG cells

NCCM was generated NC-rich NP tissue from porcine pig spines (n=6) pre-conditioned in high glucose DMEM with, 10% ITS, 50 µg/mL Ascorbic acid, 1% Penicillin/Streptomycin and 0.5 Fungizone for 4 days at 1% O₂ 5% CO₂, 37°C. The media was then filtered with Amicon-Ultra 15 filters and the filtrate (soluble factors) re-suspended in an equal volume of Basal serum-free media. NCCM was either used directly or predigested with chondroitinase ABC prior to addition to SH-SY5Y or DRG cells.

Image analysis of neurite outgrowth

Figure 2. Image analysis of neurite growth

A representative phase contrast image of SH-SY5Y cells at x10 magnification captured using a Zeiss inverted microscope and Axiovision software. A neurite was defined as a cell process greater than 20 μm , as shown in red. For branching neurites only the longest branch was traced and only cells with the entire cell body and neurite in the field of view were included. The % neurite expressing cells, mean neurite length, total # of neurites, and cell number were calculated for each image using ImageJ software.

Figure 3. Live/Dead staining of SH-SY5Y cells with Calcein & Ethidium

SH-SY5Y cells demonstrated high viability in all groups tested: Basal and 10 and 100 % NCCM as indicated by the majority of cells staining green with calcein and fewer dead cells stained red with ethidium (A). No significant differences were observed in cell viability between Basal and NCCM groups (B). Images captured at x10 magnification.

Figure 4. NCCM inhibits neurite growth of human SH-SY5Y cells with no dose effect

SH-SY5Y cells in Basal media treated with 40 ng/mL PDGF for 48hrs demonstrated an elongated morphology with long neurites (A) however addition of 10 and 100% NCCM caused cells to exhibit a more spread-out appearance with fewer neurites (B & C). Images were captured at 10x magnification. Quantitative analysis of neurite growth demonstrated significantly reduced % neurite expressing cells with NCCM at 10 and 100% compared to Basal (D). We also observed significant decreases in mean neurite length with 10% and 100% NCCM compared to Basal controls (E) ($P < 0.05$), but no differences were observed for total number of neurites (F).

Figure 5. CS is the most abundant GAG in NCCM and C-6-S the most abundant disaccharide GAG in NCCM was characterized using multiple digestions using (A) Chon-ABC specific for CS and DS, Chon-B specific for DS only, keratanase for KS and heparanase for HS. The DMB analysis indicated that Chon-ABC was the only enzyme at all doses tested to significantly decrease the amount of GAG in NCCM compared to untreated controls suggesting that CS is the most abundant GAG in NCCM ($P < 0.05$). Further characterization using liquid chromatography mass spectroscopy (LC-MS) identified C-6-S as the most abundant disaccharide in NCCM (Figure 6B) ($P < 0.05$).

Figure 6. Intact GAGs in NCCM such as CS are necessary to inhibit neurite growth of human SH-SY5Y cells

NCCM was pre-treated with 0.05U/mL of Chon ABC for 30 minutes at 37°C and then added to SH-SY5Y cells seeded as described previously. SH-SY5Y cells treated with NCCM digested with Chon-ABC (NCCM + Chon-ABC) demonstrated a similar cellular morphology (C) as the Basal control group (A) and this was confirmed after quantitative analysis of neurite growth, where NCCM+Chon-ABC group restored the % of neurite expressing cells to Basal levels (D) ($P < 0.05$). NCCM pre-treated with Chon-ABC significantly increased mean neurite length and total # neurites compared to NCCM alone (E & F) ($P < 0.05$).

Figure 7. Intact GAGs in NCCM such as CS are necessary to inhibit neurite growth of rat DRGs NCCM was pre-treated with 0.05U/mL of Chon ABC for 30 minutes at 37°C and added to rat DRGs. Rat DRGs demonstrated no differences in cell morphology between groups, however differences in the number of neurites was observed with NCCM (B) showing the fewest compared to Basal (A) and NCCM + Chon-ABC (C) groups. NCCM + Chon-ABC restored neurite growth to Basal levels compared to NCCM alone for parameters of % neurite expressing cells (D), mean neurite length (E) and total number of neurites (F) ($P < 0.05$).